Comorbidities in pediatric alopecia areata.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
14
02
2020
accepted:
12
05
2020
pubmed:
13
6
2020
medline:
15
5
2021
entrez:
13
6
2020
Statut:
ppublish
Résumé
Comorbidities are associated with higher health care costs, complex management, and poorer health outcomes. Identification and treatment of comorbid conditions in paediatric alopecia areata (AA) patients could provide an opportunity to improve health outcomes. To determine the prevalence of comorbidities among paediatric patients with AA using a large de-identified aggregated patient database. This is a cross-sectional study using aggregated health record data through April 1, 2019. Patients ≤18 years of age, with alopecia areata (n = 3510) and without alopecia areata (n = 8 310 710) were identified. The primary outcome was the prevalence of comorbidities among AA patients. Of the 8 314 220 paediatric patients, 3510 (1570 males and 1940 females) had a diagnosis of alopecia areata. The most common comorbidities included atopic dermatitis (17.4% vs. 2.2% controls, OR 9.2, 95% CI 8.55-10.18, P < 0.001), anaemia (7.7% vs. 2.4% controls, OR 3.4, 95% CI 3.06-3.92, P < 0.001), obesity (5.7% vs. 1.1% controls, OR 5.6, 95% CI 4.76-6.34, P < 0.001), vitamin D deficiency (5.1% vs. 0.4% controls, OR 14.7, 95% CI 13.5-18.1, P < 0.001), hypothyroidism (2.6% vs. 0.2% controls, OR 12, 95% CI 10.73-15.9, P < 0.001), vitiligo (1.4% vs. 0.04% controls, OR 32.2, 95% CI 24.01-42.1, P < 0.001), psoriasis (1.4% vs. 0.07% controls, OR 20.6, 95% CI 15.55-27.2, P < 0.001), hyperlipidemia (1.4% vs. 0.2% controls, OR 5.9, 95% CI 4.4-7.7, P < 0.001), and depression (2.6% vs. 0.6% controls, OR 4.8, 95% CI 5.09-9.45, P < 0.001). Findings from this study suggest that children with AA are more likely to have certain autoimmune and metabolic disorders than the general paediatric population. Paediatric AA patients display a severe burden of autoimmune and metabolic diseases, thus in daily practice, dermatologists might consider multidisciplinary management in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Comorbidities are associated with higher health care costs, complex management, and poorer health outcomes. Identification and treatment of comorbid conditions in paediatric alopecia areata (AA) patients could provide an opportunity to improve health outcomes.
OBJECTIVES
OBJECTIVE
To determine the prevalence of comorbidities among paediatric patients with AA using a large de-identified aggregated patient database.
METHODS
METHODS
This is a cross-sectional study using aggregated health record data through April 1, 2019. Patients ≤18 years of age, with alopecia areata (n = 3510) and without alopecia areata (n = 8 310 710) were identified. The primary outcome was the prevalence of comorbidities among AA patients.
RESULTS
RESULTS
Of the 8 314 220 paediatric patients, 3510 (1570 males and 1940 females) had a diagnosis of alopecia areata. The most common comorbidities included atopic dermatitis (17.4% vs. 2.2% controls, OR 9.2, 95% CI 8.55-10.18, P < 0.001), anaemia (7.7% vs. 2.4% controls, OR 3.4, 95% CI 3.06-3.92, P < 0.001), obesity (5.7% vs. 1.1% controls, OR 5.6, 95% CI 4.76-6.34, P < 0.001), vitamin D deficiency (5.1% vs. 0.4% controls, OR 14.7, 95% CI 13.5-18.1, P < 0.001), hypothyroidism (2.6% vs. 0.2% controls, OR 12, 95% CI 10.73-15.9, P < 0.001), vitiligo (1.4% vs. 0.04% controls, OR 32.2, 95% CI 24.01-42.1, P < 0.001), psoriasis (1.4% vs. 0.07% controls, OR 20.6, 95% CI 15.55-27.2, P < 0.001), hyperlipidemia (1.4% vs. 0.2% controls, OR 5.9, 95% CI 4.4-7.7, P < 0.001), and depression (2.6% vs. 0.6% controls, OR 4.8, 95% CI 5.09-9.45, P < 0.001).
CONCLUSIONS
CONCLUSIONS
Findings from this study suggest that children with AA are more likely to have certain autoimmune and metabolic disorders than the general paediatric population. Paediatric AA patients display a severe burden of autoimmune and metabolic diseases, thus in daily practice, dermatologists might consider multidisciplinary management in these patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2898-2901Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Nanda A, Al-Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. Pediatr Dermatol 1999; 16: 6-11.
Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol 2018; 79: 556-558.e551.
Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 466-477.e16.
Chu SY, Chen YJ, Tseng WC et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol 2011; 65: 949-956.
Lee NR, Kim BK, Yoon NY, Lee SY, Ahn SY, Lee WS. Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients. Ann Dermatol 2014; 26: 722-726.
Han TY, Lee JH, Noh TK et al. Alopecia areata and overt thyroid diseases: a nationwide population-based study. J Dermatol 2018; 45: 1411-1417.
Sorrell J, Petukhova L, Reingold R, Christiano A, Garzon M. Shedding light on alopecia areata in pediatrics: a retrospective analysis of comorbidities in children in the national alopecia areata registry. Pediatr Dermatol 2017; 34: e271-e272.
Wohlmuth-Wieser I, Osei JS, Norris D et al. Childhood alopecia areata-data from the national alopecia areata registry. Pediatr Dermatol 2018; 35: 164-169.
The IBM Explorys Platform. Liberate Your Healthcare Data. IBM Corporation. [WWW document] 2016. URL https://www.ibm.com/downloads/cas/4P0QB9JN (last accessed: 24 July 2019).
IBM Corporation. The Data Curation Process. Watson-Health Informatics -Overview of Mapping, Standardization, and Indexing. IBM Corporation. [WWW document] 2016. URL https://www.ibm.com/downloads/cas/JBNOXQK4 (last accessed: 24 July 2019).
Lee HH, Gwillim E, Patel KR et al. Epidemiology of alopecia areata, ophiasis, totalis and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 82: 675-682.
Caldwell CC, Saikaly SK, Dellavalle RP, Solomon JA. Prevalence of pediatric alopecia areata among 572,617 dermatology patients. J Am Acad Dermatol 2017; 77: 980-981.
Tamer E, Ilhan MN, Polat M, Lenk N, Alli N. Prevalence of skin diseases among pediatric patients in Turkey. J Dermatol 2008; 35: 413-418.
Lee H, Jung SJ, Patel AB, Thompson JM, Qureshi A, Cho E. Racial characteristics of alopecia areata in the United States. J Am Acad Dermatol 2019; S0190-9622(19)32299-6.
Thompson JM, Park MK, Qureshi AA, Cho E. Race and alopecia areata amongst US Women. J Investig Dermatol Symp Proc 2018; 19: S47-S50.
Wang E, Lee JS, Tang M. Current treatment strategies in pediatric alopecia areata. Indian J Dermatol 2012; 57: 459-465.
Pires MC, Martins JM, Montealegre F, Gatti FR. Vitiligo after diphencyprone for alopecia areata. Dermatol Res Pract 2010; 2010: 171265.
Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 2014; 30: 96-102.
Kumar KJ, Kumar MS, Kumar TS, Chavan A. Diffuse scalp hair loss due to levothyroxine overdose. Indian Dermatol Online J 2015; 6(Suppl 1): S58-S60.
Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med 2019; 18: 955-959.